List of Excipients in Branded Drug FENTANYL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bryant Ranch Prepack	FENTANYL	fentanyl	63629-4765	COPOVIDONE K25-31
Dispensing Solutions Inc	FENTANYL	fentanyl	68258-3040	COPOVIDONE
Mayne Pharma	FENTANYL BUCCAL	fentanyl citrate	51862-634	ANHYDROUS CITRIC ACID
Mayne Pharma	FENTANYL BUCCAL	fentanyl citrate	51862-634	MAGNESIUM STEARATE
Mayne Pharma	FENTANYL BUCCAL	fentanyl citrate	51862-634	MANNITOL
Mayne Pharma	FENTANYL BUCCAL	fentanyl citrate	51862-634	SODIUM BICARBONATE

Generic Drugs Containing FENTANYL

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	fentanyl	0378-9119	DIMETHICONE
Mylan Pharmaceuticals Inc	fentanyl	0378-9119	TRIMETHYLSILYL TREATED DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER
Aveva Drug Delivery Systems Inc	fentanyl	3215-7701	ISOPROPYL MYRISTATE
Aveva Drug Delivery Systems Inc	fentanyl	3215-7701	OCTYLDODECANOL
Aveva Drug Delivery Systems Inc	fentanyl	3215-7701	POLYBUTENE
Aveva Drug Delivery Systems Inc	fentanyl	3215-7701	POLYISOBUTYLENE

What are the Most Frequently-Used Excipients in FENTANYL?

# Of NDCs	Excipient
2	ALCOHOL
5	DIMETHICONE
21	ISOPROPYL MYRISTATE
2	MINERAL OIL
19	OCTYLDODECANOL
18	POLYBUTENE

Fentanyl Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Fentanyl is a mature active pharmaceutical ingredient with limited compound-patent value but continuing formulation, delivery-device, manufacturing, and controlled-substance compliance opportunities. The strongest commercial positions are in abuse-deterrent oral transmucosal systems, high-performance transdermal patches, hospital delivery systems, and differentiated nasal or buccal products. Generic injection and patch markets are established, while transmucosal products remain more protected by formulation complexity, device requirements, clinical performance, and the TIRF Risk Evaluation and Mitigation Strategy (REMS).

What pharmaceutical formulations contain fentanyl?

Fentanyl is marketed in multiple dosage forms, each creating a different excipient and intellectual-property profile.

Dosage form	Representative products	Primary excipient function	Commercial barrier
Injection	Generic fentanyl citrate injection	pH control, tonicity, solubilization, preservative control	Low-to-moderate; sterile manufacturing
Transdermal patch	Duragesic and generics	Adhesion, skin permeation, reservoir or matrix control	Moderate; adhesive and delivery performance
Buccal tablet	Fentora	Mucoadhesion, rapid disintegration, saliva-mediated delivery	High relative to conventional tablets
Oral transmucosal lozenge	Actiq	Matrix formation, dissolution control, taste management	High; TIRF REMS and product-specific exposure
Sublingual spray	Subsys	Solubilization, spray viscosity, dose metering	High; device and abuse-control requirements
Nasal spray	Lazanda	Solubilization, viscosity, spray deposition, dose uniformity	High; device and nasal tolerability
Iontophoretic transdermal system	Ionsys	Hydrogel electrolyte system and electrode compatibility	Very high; combination-product manufacturing

The choice of excipient system determines fentanyl release, mucosal or dermal absorption, dose uniformity, storage stability, abuse potential, and regulatory complexity.

How should excipients be selected for fentanyl products?

The optimal excipient strategy depends on the delivery route. Fentanyl is highly potent, so small changes in content uniformity or absorption can produce clinically meaningful exposure differences. FDA product-specific guidance and comparative pharmacokinetic testing are therefore central to development planning.[1]

What excipients are used in fentanyl injections?

Fentanyl citrate injection generally uses a relatively simple aqueous system. Typical formulation functions include:

• Sterile water as the vehicle.
• Sodium chloride or another tonicity agent.
• pH adjustment with acids or bases.
• Buffering where needed.
• Preservative systems in multidose presentations, subject to compatibility and regulatory limits.

The commercial priority is not excipient novelty. It is reliable sterile filling, low extractables and leachables, container-closure integrity, and compatibility with syringes, infusion sets, and hospital pumps.

A differentiated injectable product could use ready-to-administer packaging, low-sorbtion containers, premixed concentrations, or a preservative-free presentation. These changes may support hospital contracting even when they provide limited patent protection.

What excipients are used in fentanyl transdermal patches?

Transdermal fentanyl systems generally rely on:

• Pressure-sensitive adhesives.
• Polymer matrices or drug reservoirs.
• Skin-permeation control.
• Release liners and backing layers.
• Stabilizers and solvents compatible with the adhesive system.

Commercially relevant excipient and material variables include adhesive drug loading, crystallization control, cold-flow resistance, skin adhesion over several days, residual drug after use, and protection against accidental transfer.

The strongest patent claims in this segment typically cover the complete patch architecture rather than a single conventional excipient. Claim scope may include adhesive composition, fentanyl concentration, multilayer construction, release profile, backing material, or manufacturing sequence.

What excipients are used in buccal and sublingual fentanyl products?

Buccal and sublingual systems may use hydrophilic polymers, mucoadhesive polymers, fillers, binders, disintegrants, sweeteners, flavoring agents, and pH modifiers. Candidate excipient classes include:

• Hydroxypropyl methylcellulose and related cellulose derivatives.
• Polyacrylic acid or carbomer systems.
• Polyvinylpyrrolidone.
• Mannitol and other rapidly dissolving fillers.
• Crospovidone or comparable disintegrants.
• Citric acid, citrate salts, and other pH modifiers.
• Taste-masking agents and noncaloric sweeteners.

The development objective is rapid mucosal dissolution without uncontrolled swallowing. A formulation that increases swallowed fentanyl can alter exposure and weaken bioequivalence or clinical differentiation.

Excipient selection must also account for saliva volume, mucosal residence time, tablet erosion, local irritation, and patient handling. Novel mucoadhesive combinations may create formulation patent opportunities, but conventional excipients alone rarely provide durable exclusivity.

What excipients are used in fentanyl nasal sprays?

Nasal sprays require a solution or suspension with tight control of:

• Fentanyl solubility.
• Osmolality.
• pH.
• Viscosity.
• Droplet-size distribution.
• Spray-plume geometry.
• Microbial quality.
• Nasal tolerability.

Viscosity modifiers can increase nasal residence time but may reduce spray performance. Surfactants and cosolvents can improve solubility but may increase irritation. The device and formulation must be developed together because actuator performance affects dose deposition and systemic absorption.

A defensible patent estate can cover the formulation, concentration range, viscosity, pH, spray device, metered-dose accuracy, and method of treating breakthrough cancer pain.

What commercial opportunities exist for fentanyl excipients?

How can abuse-deterrent excipients create value?

Abuse-deterrent strategies may use physical, chemical, or pharmacokinetic barriers. Examples include:

• Gelling systems that resist extraction.
• Rapidly hardening matrices.
• High-viscosity systems that limit syringeability.
• Sequestered or immobilized drug.
• Dose forms that resist crushing and powder formation.
• Taste or irritation mechanisms that discourage chewing or excessive administration.

FDA evaluates abuse-deterrent products against specific abuse routes rather than treating abuse deterrence as a general label attribute.[2] A product may receive abuse-deterrent labeling only when supported by the applicable laboratory, pharmacokinetic, and clinical evidence.

For fentanyl, abuse-deterrence claims face a difficult balance. The product must preserve predictable therapeutic delivery while limiting manipulation. Because fentanyl is potent at very low doses, excipient systems that create dose segregation or extraction variability can increase regulatory risk.

What excipient opportunities exist in transdermal fentanyl?

Commercial opportunities include:

1. Low-residual-drug patches that reduce post-use exposure.
2. Stronger adhesives for sweating, movement, and long wear.
3. Skin-friendly adhesives for elderly or cachectic patients.
4. Matrix systems with improved dose uniformity.
5. Tamper-evident packaging and disposal systems.
6. Patches with reduced accidental transfer risk.
7. Manufacturing processes that reduce fentanyl loss during coating and lamination.

The most valuable innovation may be a combined patch, backing, adhesive, and packaging platform. A conventional adhesive substitution is less likely to support meaningful exclusivity unless it produces a measurable clinical or manufacturing advantage.

What excipient opportunities exist in nasal fentanyl?

Nasal products can be differentiated through:

• Improved spray plume and deposition.
• Reduced postnasal drip.
• Lower irritation.
• Longer shelf life.
• Lower preservative burden.
• Greater dose consistency under temperature variation.
• Pediatric-resistant or tamper-resistant packaging, where appropriate.
• Abuse-resistant metering systems.

Nasal delivery also creates device-related patent opportunities. However, device changes may trigger combination-product review and human-factors testing.

What excipient opportunities exist in hospital fentanyl products?

Hospital products compete on workflow and safety rather than compound innovation. Commercially relevant opportunities include:

• Ready-to-use syringes.
• Standardized concentrations.
• Premixed infusion bags.
• Barcode-enabled packaging.
• Reduced preparation steps.
• Low-sorption container materials.
• Longer in-use stability.
• Improved visibility of particulate contamination.
• Closed-system transfer compatibility.

These products may secure hospital formulary access without relying on extensive patent protection. Manufacturing reliability and supply continuity can be more important than formulation differentiation.

What patents protect fentanyl products?

Fentanyl itself is an old synthetic opioid, and broad composition-of-matter protection is expired. Current protection is product-specific and generally focuses on formulation, dosage form, delivery technology, device architecture, manufacturing, packaging, and method of use.

Patent category	Typical claim subject	Relative commercial value
Composition of matter	Fentanyl molecule or salt	Minimal for new entrants
Formulation	Excipient ratios, pH, viscosity, dissolution, permeation	Moderate to high
Delivery device	Metering, spray, patch, electrode, applicator	High where device performance is essential
Manufacturing	Coating, mixing, loading, sterilization, assembly	Moderate; difficult to detect infringement in some cases
Method of use	Breakthrough cancer pain, postoperative analgesia	Variable; vulnerable to carve-outs and litigation
Packaging and disposal	Child resistance, tamper evidence, residual-drug control	Moderate
Abuse deterrence	Extraction resistance, manipulation resistance, pharmacokinetic control	Potentially high if clinically validated

Orange Book status must be reviewed by product and NDA. FDA Orange Book listings can change through patent-listing updates, delisting, expiration, litigation certification, and regulatory withdrawal.[3] A company should not treat an old fentanyl product label or historical patent list as a current freedom-to-operate position.

When does fentanyl lose exclusivity?

Fentanyl has already lost broad market exclusivity in injectable and transdermal forms. Generic fentanyl citrate injections and transdermal systems have been available for years. Branded transmucosal and nasal products retain greater practical protection because generic applicants must address product-specific bioequivalence, device performance, clinical pharmacology, and controlled-substance controls.

Market segment	Exclusivity position
Fentanyl injection	Mature generic market
Transdermal patch	Mature generic market with formulation and manufacturing barriers
Buccal tablet	More limited generic competition; product-specific bioequivalence burden
Oral transmucosal lozenge	Restricted market with TIRF REMS and abuse-risk concerns
Nasal spray	Device and formulation complexity limit rapid substitution
Iontophoretic system	Specialized combination-product pathway

Regulatory exclusivity is separate from patent protection. New dosage forms may receive three years of FDA exclusivity for qualifying clinical investigations, while new chemical entities are not relevant to ordinary fentanyl reformulations because fentanyl is an established active ingredient.[4]

What is the FDA regulatory status of fentanyl products?

FDA-approved fentanyl products include injectable, transdermal, buccal, oral transmucosal, nasal, and specialized delivery systems. The approval status of individual products can change because of discontinuation, safety actions, manufacturing issues, or commercial withdrawal.

Transmucosal immediate-release fentanyl products are subject to the TIRF REMS because of the risk of misuse, abuse, addiction, overdose, and death. The program imposes requirements on prescribers, pharmacies, distributors, and patients.[5]

A new fentanyl product must address:

• Controlled-substance scheduling.
• Abuse and diversion controls.
• Accurate low-dose manufacturing.
• Human-factors validation for delivery devices.
• Product-specific pharmacokinetics.
• Nasal or mucosal tolerability.
• Container-closure and packaging controls.
• REMS obligations where applicable.
• Postmarket surveillance.

Which companies are challenging fentanyl products?

Competition is fragmented. Generic manufacturers have challenged or entered the injection and transdermal markets, while specialized developers have pursued buccal, sublingual, nasal, and iontophoretic products.

The main competitive groups are:

• Large generic manufacturers supplying injectable and patch products.
• Branded opioid companies with transmucosal or nasal technologies.
• Drug-delivery companies with mucoadhesive, spray, or transdermal platforms.
• Hospital-product suppliers offering ready-to-administer fentanyl.
• Contract development and manufacturing organizations with controlled-substance capabilities.

Publicly visible Paragraph IV activity varies by product and changes as patents expire or are delisted. A current review must be performed in the FDA Orange Book, FDA Paragraph IV notice records, and relevant federal court dockets. Patent litigation is more likely for branded transmucosal and nasal products than for basic injectable fentanyl.

What patent litigation and settlement risks affect fentanyl?

Fentanyl litigation can involve:

• Paragraph IV certifications against listed formulation or method patents.
• ANDA litigation under the Hatch-Waxman framework.
• Device patent disputes involving spray actuators or patch construction.
• Trade-secret claims involving manufacturing processes.
• Contract disputes over controlled-substance supply.
• REMS access and shared-system disputes.
• Product-liability litigation, which can affect commercial launch decisions even without patent infringement.

Settlement agreements may include licensed entry dates, authorized generic arrangements, supply provisions, or restrictions on product labels. A settlement that permits an earlier launch can materially reduce the value of a remaining patent.

How strong is the fentanyl patent estate?

The estate is strongest when it combines several independently valuable layers:

1. A differentiated delivery device.
2. A formulation with measurable pharmacokinetic or tolerability advantages.
3. A manufacturing process that is difficult to design around.
4. A method-of-use position tied to a specific patient population.
5. Regulatory exclusivity or REMS-related commercial friction.
6. Trade secrets covering loading, coating, or assembly.

A patent covering only a known excipient in a routine concentration range is usually weaker. A patent covering a narrow excipient combination that controls fentanyl delivery, improves stability, reduces residual drug, or prevents manipulation has greater commercial relevance.

How does fentanyl compare with competing opioid delivery systems?

Attribute	Fentanyl	Buprenorphine	Oxycodone	Hydromorphone
Potency	Very high	High	Moderate	High
Transdermal use	Established	Established	Limited	Limited
Nasal delivery opportunity	Established	Available in some products	Limited	Limited
Dose-uniformity risk	High	High	Moderate	High
Abuse-deterrence value	High	High	High	High
Generic competition	Extensive in legacy forms	Extensive in some forms	Extensive	Extensive
Excipient differentiation	Strongest in delivery systems	Strong in films and patches	Strong in abuse-deterrent tablets	More limited

Fentanyl offers greater value per unit dose but also carries a higher safety and regulatory burden. That combination supports premium delivery technologies but reduces the commercial viability of marginal reformulations.

What geographic coverage matters for fentanyl excipients?

United States protection depends on FDA approval, Orange Book listings, Hatch-Waxman litigation, controlled-substance regulation, and REMS obligations. European protection depends on national or centralized marketing authorization, European patent validation, supplementary protection certificate history where applicable, and national litigation.

Key geographic differences include:

• FDA Orange Book listing has no direct equivalent across all European jurisdictions.
• TIRF REMS is a U.S.-specific regulatory structure.
• Controlled-substance distribution rules differ by country.
• Nasal and buccal products may face different clinical and device requirements.
• Patent term, SPC eligibility, and generic litigation procedures differ across Europe.
• Manufacturing sites may require separate narcotics licenses and inspections.

A global platform should use excipients with established regulatory histories in each target market. A novel excipient may delay approval even when the active ingredient is well understood.

What generic launch risks exist for fentanyl?

Generic entry is most likely where the product has:

• A simple aqueous injection.
• A conventional transdermal patch.
• No active device patent.
• Limited formulation complexity.
• Straightforward analytical methods.
• A clear therapeutic equivalence pathway.

Launch risk is higher for:

• Metered nasal sprays.
• Buccal and sublingual products.
• Abuse-deterrent systems.
• Iontophoretic delivery.
• Products with narrow therapeutic exposure windows.
• Products subject to device sameness or human-factors requirements.

Carve-out strategies may allow a generic to omit a patented method of use. That can reduce the practical scope of a use patent, especially when the remaining indication is difficult to distinguish in pharmacy or clinical practice.

What licensing deals are available in fentanyl delivery?

Licensing opportunities are most credible in technology rather than in fentanyl itself. Potential deal assets include:

• Mucoadhesive film platforms.
• Nasal spray pumps and actuators.
• Low-residual-drug patch systems.
• Abuse-deterrent polymer matrices.
• Ready-to-use sterile packaging.
• Controlled-substance manufacturing capacity.
• Analytical methods for low-dose uniformity and residual fentanyl.

A licensee will typically evaluate freedom to operate, controlled-substance handling capability, clinical bridging requirements, device ownership, manufacturing yield, and the ability to support REMS obligations.

What is the revenue exposure for fentanyl products?

Revenue exposure is concentrated in delivery systems rather than the active ingredient. Basic injectable fentanyl is exposed to price erosion from multiple generic suppliers. Transdermal patches can retain value through supply reliability, adhesion performance, packaging, and contracting. Branded transmucosal and nasal products have higher gross-margin potential but face lower eligible-patient volumes, strict prescribing controls, and substantial compliance costs.

The most defensible commercial model combines:

• A differentiated formulation.
• A proprietary or protected delivery system.
• A manufacturing advantage.
• A clinically relevant safety or usability benefit.
• A controlled-substance compliance infrastructure.

Key Takeaways

• Fentanyl compound patents are expired; commercial protection depends on formulation, device, manufacturing, packaging, and use claims.
• Injectable fentanyl is a mature generic market with opportunities in ready-to-use presentation and hospital workflow.
• Transdermal patches remain commercially relevant, especially where adhesive performance, residual-drug reduction, and transfer prevention are differentiated.
• Buccal, sublingual, and nasal products offer stronger formulation and device opportunities but carry higher regulatory and REMS burdens.
• Abuse-deterrent excipients can create value only when the performance is measurable and clinically compatible.
• Orange Book and Paragraph IV analysis must be conducted by specific NDA and formulation.
• Biosimilar risk does not apply because fentanyl is a small-molecule drug, not a biologic.
• The strongest platform strategy is a formulation-device-manufacturing package rather than a single-excipient patent.

FAQs

Is fentanyl eligible for biosimilar competition?

No. Fentanyl is a chemically synthesized small-molecule drug. Competition occurs through abbreviated new drug applications, product-specific bioequivalence, and Hatch-Waxman patent procedures, not the biosimilar pathway.

Which fentanyl dosage form offers the best excipient patent opportunity?

Buccal, sublingual, nasal, and abuse-deterrent systems generally offer more formulation patent potential than injectable fentanyl. Transdermal systems can also support valuable claims when the adhesive, matrix, release profile, and transfer-control properties are linked.

Can a novel excipient extend fentanyl exclusivity?

A novel excipient may support a new formulation patent and regulatory differentiation, but it does not automatically extend exclusivity for the active ingredient. The excipient must produce a defensible technical and clinical advantage.

Are fentanyl formulation patents listed in the Orange Book?

Some product-specific formulation, device, and method-of-use patents may be listed. Listing depends on the approved NDA and FDA requirements. The Orange Book must be reviewed for the specific branded product and current patent status.

What is the largest manufacturing barrier for fentanyl products?

The principal barriers are controlled-substance licensing, secure inventory control, low-dose content uniformity, containment during manufacturing, validated cleaning, specialized analytical testing, and compliant distribution.

References

1. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development

2. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abuse-deterrent-opioids-evaluation-and-labeling

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (2024). New drug product exclusivity. https://www.fda.gov/drugs/development-resources/new-drug-product-exclusivity

5. U.S. Food and Drug Administration. (2024). Transmucosal immediate-release fentanyl products risk evaluation and mitigation strategy. https://www.fda.gov/drugs/drug-safety-and-availability/transmucosal-immediate-release-fentanyl-products-risk-evaluation-and-mitigation-strategy